Chronic morphologically verified gastritis, variants of course

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background: Gastritis is a histological diagnosis, although its prevalence is decreasing in developed countries along with the prevalence of Helicobacter pylori infection. We identified H. pylori-positive (Hp+) and H. pylori-negative (Hp-) gastritis variants to analyze relationships that have not been adequately studied in previous studies.

Objective: Evaluation of the clinical, laboratory, and histological changes in the gastric mucosa in Hp+ and Hp- gastritis.

Materials and methods: We examined 122 patients (62 with Hp+ and 60 with Hp- gastritis) aged 20 to 65 years. In addition to conventional clinical and biochemical tests, the laboratory tests included the Gastropanel. For the diagnosis of Helicobacter pylori, 2-3 available methods were used for each patient. All study participants underwent esophagogastroduodenoscopy with morphological examination of biopsy specimens according to OLGA/OLGIM criteria. The vegetative status of the examined patients was assessed. All patients were prescribed treatment for gastritis, depending on the presence of Hp infection. Differences between the comparison parameters were considered statistically different at p≤0.05.

Results: Hp- gastritis was more often verified in the antral section, while Hp+ gastritis almost always affected both the antral section and the stomach body. Metaplasia according to OLGIM 0–I was observed only in 9 patients with Hp+ gastritis (p>0.05). In the vegetative status, vagotonia prevailed, in contrast to the control (p>0.05). All patients with Hp+ gastritis were prescribed anti-Helicobacter therapy. A number of patients chose a combination composition with the commercial name Pilobact® AM and bismuth tripotassium dicitrate for 14 days, had an eradication level of 87.4%. We conducted a pharmacochemical comparative analysis of the drugs included in Pilobact® AM with reference drugs and obtained their high comparability.

Conclusion: Significant differences in clinical and laboratory parameters in patients with Hp+ Hp- gastritis were revealed only in morphological data. One of the anti-Helicobacter treatment options can be the Pilobact® AM combination, which has proven both its high efficiency in clinical observations and pharmacochemical comparability with reference drugs.

全文:

受限制的访问

作者简介

Ekaterina Plotnikova

Kemerovo State Medical University

编辑信件的主要联系方式.
Email: eka-pl@rambler.ru
ORCID iD: 0000-0002-6150-1808
SPIN 代码: 4346-5012
Scopus 作者 ID: 57193910407

Dr. Sci. (Med.), Professor, Department of Postgraduate Training and Nursing, Head of the Clinical Gastroenterology Course

俄罗斯联邦, Kemerovo

A. Kutsaeva

I.A. Kolpinsky Clinical Consultative and Diagnostic Center

Email: dr.kytsaeva@vk.com
ORCID iD: 0009-0006-2396-3880

Gastroenterologist

俄罗斯联邦, Kemerovo

A. Sukhikh

Kemerovo State University

Email: suhih_as@list.ru
ORCID iD: 0000-0001-9300-5334

Cand. Sci. (Med.), Head of the Laboratory of Physicochemical Studies of Pharmacologically Active and Natural Compounds

俄罗斯联邦, Kemerovo

E. Baranova

Kemerovo State Medical University

Email: bevgn@rambler.ru

Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy and Clinical Pharmacology

俄罗斯联邦, Kemerovo

M. Sinkov

Research Institute of Complex Issues of Cardiovascular Diseases

Email: fox2you@mail.ru
ORCID iD: 0000-0002-2494-8694

Cand. Sci. (Med.), Cardiovascular Surgeon

俄罗斯联邦, Kemerovo

M. Nikonorova

Altai State Medical University

Email: ma.nikulina@mail.ru
ORCID iD: 0000-0001-6621-9310

Dr. Sci. (Med.), Associate Professor, Professor at the Department of Infectious Diseases with the Course of Continuous Professional Education

俄罗斯联邦, Barnaul

参考

  1. Toyoshima O., Nishizawa T., Sakitani K., et al. Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. JGH Open. 2020;4(5):909–14. https://dx.doi.org/10.1002/jgh3.12360
  2. Weng C.Y., Xu J.L., Sun S.P., et al. Helicobacter pylori eradication: Exploring its impacts on the gastric mucosa. World J Gastroenterol. 2021;27(31):5152–70. https://dx.doi.org/10.3748/wjg.v27.i31.5152
  3. Fock K.M., Graham D.Y., Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10(8):495–500. https://dx.doi.org/10.1038/nrgastro.2013.96
  4. Rugge M., Correa P., Di Mario F., et al. OLGA staging for gastritis: A tutorial. Digestive and Liver Disease. 2008;40(8):650–8. doi: 10.1016/j.dld.2008.02.030.
  5. Rugge M., de Boni M., Pennelli G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31(10):1104–11. https://dx.doi.org/10.1111/j.1365-2036.2010.04277.x
  6. Guarner J., Mohar A., Parsonnet J., Halperin D. The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. Cancer. 1993;71(2):297–301. https://dx.doi.org/10.1002/1097-0142(19930115)71:2<297:aid-cncr2820710205>3.0.co;2-9
  7. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. https://dx.doi.org/10.3322/caac.20107
  8. Sugano K., Tack J., Kuipers E.J., et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. https://dx.doi.org/10.1136/gutjnl-2015-309252
  9. Malfertheiner P., Megraud F., Rokkas T., et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. https://dx.doi.org/10.1136/gutjnl-2022-327745
  10. Sung J.J., Lin S.R., Ching J.Y., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119(1):7–14. https://dx.doi.org/10.1053/gast.2000.8550
  11. Haber M.M., Hunt B., Freston J.W., et al. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther. 2010;32(1):83–96. https://dx.doi.org/10.1111/j.1365-2036.2010.04310.x
  12. Peura D.A., Haber M.M., Hunt B., Atkinson S. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol. 2010;44(3):180–5. https://dx.doi.org/10.1097/MCG.0b013e3181ac9830
  13. Merchant S.H., VanderJagt T., Lathrop S., Amin M.B. Sporadic duodenal bulb gastrin-cell tumors: association with Helicobacter pylori gastritis and long-term use of proton pump inhibitors. Am J Surg Pathol. 2006;30(12):1581–7. https://dx.doi.org/10.1097/01.pas.0000213326.86992.98
  14. Sugano K. Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011;17(4):366–71. https://dx.doi.org/10.5056/jnm.2011.17.4.366
  15. Suzuki H., Nishizawa T., Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011;26(Suppl. 3):42–5. https://dx.doi.org/10.1111/j.1440-1746.2011.06629.x
  16. Miwa H., Ghoshal U.C., Fock K.M., et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012;27(4):626–41. https://dx.doi.org/10.1111/j.1440-1746.2011.07037.x.
  17. Asaka M., Kato M., Takahashi S., et al.; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15(1):1–20. https://dx.doi.org/10.1111/j.1523-5378.2009.00738.x
  18. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2001;(1):CD002096. https://dx.doi.org/10.1002/14651858.CD002096
  19. Yagi K., Nakamura A., Sekine A. Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17(1):39–45. https://dx.doi.org/10.1046/j.1440-1746.2002.02665.x
  20. Okubo M., Tahara T., Shibata T., et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion. 2011;83(3):161–6. https://dx.doi.org/10.1159/000321799
  21. Rugge M., Genta R.M. Staging and grading of chronic gastritis. Hum Pathol. 2005;36(3):228–33. https://dx.doi.org/10.1016/j.humpath.2004.12.008
  22. Mansour-Ghanaei F., Joukar F., Yeganeh S., et al. OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications. Turk J Gastroenterol. 2022;33(2):95–102. https://dx.doi.org/10.5152/tjg.2021.201154
  23. Yagi K., Nakamura A., Sekine A. Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy. 2002;34(5):376–81. https://dx.doi.org/10.1055/s-2002-25281
  24. Nagasaki N., Ito M., Boda T., et al. Identification of Helicobacter pylori-related gastric cancer risk using serological gastritis markers and endoscopic findings: a large-scale retrospective cohort study. BMC Gastroenterol. 2022;22(1):299. https://dx.doi.org/10.1186/s12876-022-02381-z
  25. Kageyama T. Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development. Cell Mol Life Sci. 2002;59(2):288–306. https://dx.doi.org/10.1007/s00018-002-8423-9
  26. Juan Cai W., Yin L., Kang Q., et al. The Serum Pepsinogen Test as a Predictor of Kazakh Gastric Cancer. Sci Rep. 2017;7:43536. https://dx.doi.org/10.1038/srep43536
  27. Zhang J., Guo J.Z., Xiao H.L., et al. Simultaneous detection of different serum pepsinogens and its primary application. World J Gastroenterol. 2010;16(24):3072–7. https://dx.doi.org/10.3748/wjg.v16.i24.3072
  28. Di Mario F., Crafa P., Barchi A., et al. Pepsinogen II in gastritis and Helicobacter pylori infection. Helicobacter. 2022;27(2):e12872. https://dx.doi.org/10.1111/hel.12872
  29. Lespessailles E., Toumi H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci. 2022;23(18):10733. https://dx.doi.org/10.3390/ijms231810733
  30. Castellana C., Pecere S., Furnari M., et al. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021;131(6):541–9. https://dx.doi.org/10.20452/pamw.15997
  31. Chinzon D., Domingues G., Tosetto N., Perrotti M. Safety of Long-term Proton Pump Ingibitors: Facts and Myths. Arq Gastroenterol. 2022;59(2):219–25. https://dx.doi.org/10.1590/S0004-2803.202202000-40
  32. Kotelevets S.M., Chekh S.A., Chukov S.Z. Effectiveness of serological markers of gastric mucosal atrophy in the gastric precancer screening and in cancer prevention. World J Gastrointest Endosc. 2024;16(8):462–71. https://dx.doi.org/10.4253/wjge.v16.i8.462
  33. Wang R., Chen X.Z. Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). Sci Rep. 2020;10(1):4523. https://dx.doi.org/10.1038/s41598-020-61472-7
  34. Gašenko E., Bogdanova I., Sjomina O., et al. Assessing the utility of pepsinogens and gastrin-17 in gastric cancer detection. Eur J Cancer Prev. 2023;32(5):478–84. https://dx.doi.org/10.1097/CEJ.0000000000000791
  35. Li Y., Zhao Y., Li Y., et al. Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. J Physiol Biochem. 2021;77(1):93–104. https://dx.doi.org/10.1007/s13105-020-00780-y
  36. Zeng J., Shen Y., Xu S., Yang R. Analysis of gastrin-17 and its related influencing factors in physical examination results. Immun Inflamm Dis. 2023;11(10):e993. https://dx.doi.org/10.1002/iid3.993
  37. Qin Y., Geng J.X., Huang B. Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases. World J Gastrointest Oncol. 2023;15(7):1174–81. https://dx.doi.org/10.4251/wjgo.v15.i7.1174
  38. Capelle L.G., de Vries A.C., Haringsma J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–8. https://dx.doi.org/10.1016/j.gie.2009.12.029
  39. Ben Slama S., Ben Ghachem D., Dhaoui A., et al. Gastrites chroniques à hélicobacter pylori: évaluation des systèmes OLGA et OLGIM [Helicobacter pylori gastritis: assessment of OLGA and OLGIM staging systems]. Pan Afr Med J. 2016;23:28. French. https://dx.doi.org/10.11604/pamj.2016.23.28.8839
  40. Плотникова Е.Ю. и др. Программа для ЭВМ «Корвег». Свидетельство об официальной регистрации № 200061883 от 8 сентября 2000 г. Российского Агентства по патентам и товарным знакам. [Plotnikova E.Yu. et al. Computer program «Korveg». Certificate of official registration No. 200061883 dated September 8, 2000 of the Russian Agency for Patents and Trademarks. (In Russ.)].
  41. Клинические рекомендации. Гастрит и дуоденит. URL: https://cr.minzdrav.gov.ru/view-cr/708_2 [Clinical recommendations. Gastritis and duodenitis. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/708_2
  42. Sonnenberg A., Genta R.M. Changes in the Gastric Mucosa With Aging. Clin Gastroenterol Hepatol. 2015;13(13):2276–81. https://dx.doi.org/10.1016/j.cgh.2015.02.020
  43. Sipponen P., Maaroos H.I. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657–67. https://dx.doi.org/10.3109/00365521.2015.1019918
  44. Agréus L., Hellström P.M., Talley N..J., et al. Towards a healthy stomach? Helicobacter pylori prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterol J. 2016;4(5):686–96. https://dx.doi.org/10.1177/2050640615623369
  45. Muszyński J., Ziółkowski B., Kotarski P., et al. Gastritis – facts and doubts. Prz Gastroenterol. 2016;11(4):286–95. https://dx.doi.org/10.5114/pg.2016.57793
  46. Cutler A.F., Prasad V.M., Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med. 1998;105(1):18–20. https://dx.doi.org/10.1016/s0002-9343(98)00134-x
  47. Nordenstedt H., Graham D.Y., Kramer J.R., et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108(1):65–71. https://dx.doi.org/10.1038/ajg.2012.372
  48. Zavros Y., Rieder G., Ferguson A., et al. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology. 2002;122(1):119–33. https://dx.doi.org/10.1053/gast.2002.30298
  49. Минушкин О.Н., Зверков И.В., Володин Д.В. и др. Эффективность препарата «Пилобакт АМ» в эрадикационной терапии язвенной болезни двенадцатиперстной кишки. Врач. 2008;(5):67–9. [Minushkin O.N., Zverkov I.V., Volodin D.V., et al. Efficiency of the drug «Pilobact AM» in eradication therapy of duodenal ulcer. Vrach. 2008;(5):67–9. (In Russ.)].
  50. Кантуринова А.З., Тулина М.К., Жетписова Л.Б. Пилобакт Нео в лечении язвенной болезни. Медицинский журнал Западного Казахстана. 2011;4(32):67–9. [Kanturinova A.Z., Tulina M.K., Zhetpisova L.B. Pilobact Neo in the treatment of peptic ulcer disease. Medical Journal of Western Kazakhstan. 2011;4(32):67–9. (In Russ.)].
  51. Зангиева Е.В., Ивашев М.Н. Эффективность Пилобакта. Международный журнал экспериментального образования. 2017;1:115–6. [Zangieva E.V., Ivashev M.N. Efficiency of Pilobact. International Journal of Experimental Education. 2017;1:115–6. (In Russ.)].
  52. Старостин Б.Д. Модифицированная Пилобакт АМ-основанная терапия. Русский медицинский журнал. 2019;5:8–12. [Starostin B.D. Modified Pilobact AM-based therapy. Russkiy meditsinskiy zhurnal. 2019;5:8–12. (In Russ.)].
  53. Пахомова И.Г. Современные возможности повышения эффективности эрадикационной терапии на клиническом примере. Медицинский совет. 2022;(15):28–34. [Pakhomova I.G. Modern possibilities of increasing the effectiveness of eradication therapy using a clinical example. Meditsinskiy sovet. 2022;(15):28–34. (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2022-16-15-28-34
  54. Барановский А.Ю., Бордин Д.С., Эмбутниекс (Таранченко) Ю.В. и др. Европейский регистр Helicobacter pylori (Hp-EuReg): анализ данных 2360 больных, получавших терапию первой линии в России. Терапевтический архив. 2018;90(2):35–41. [Baranovsky A.Yu., Bordin D.S., Embutnieks (Taranchenko) Yu.V. et al. European Helicobacter pylori Registry (Hp-EuReg): analysis of data from 2360 patients receiving first-line therapy in Russia. Terapevticheskii arkhiv. 2018;90(2):35–41. (In Russ.)]. https://dx.doi.org/10.26442/terarkh20189023542

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure. 1. IR spectroscopy - comparison of clarithromycin and amoxicillin, included in Pilobact® AM with reference antibiotics

下载 (175KB)
索引源数据
3. Figure. 2. HPLC spectra of various omeprazoles

下载 (125KB)
索引源数据

版权所有 © Bionika Media, 2025